BACKGROUND
Anthracycline-free TCHP and anthracycline-based AC-THP are both used as neoadjuvant dual anti-HER2 regimens for HER2-positive breast cancer, but direct comparisons accounting for HER2 immunohistochemistry (IHC) intensity are lacking. Because IHC 3+ tumors respond substantially better to dual blockade, any be...
B. Sharaf, F. Tamimi, Mohammad Alzoubi et al.· Cancer Treatment and Researc...· 0 citations
A narrative review of phase II/III trials reporting radiographic progression-free survival (rPFS) or overall survival (OS) in mCRPC, including congress data, to June 2026, graded on a five-level evidence hierarchy to propose a hypothesis-generating four-track framework for discussion between clinicians and patients.
B. Sharaf, M. Alrwashdeh, O. El Khatib et al.· Cancers· 0 citations
In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.
B. Sharaf, T. Al-Batsh, Suhaib Khater et al.· Breast Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.